AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02812693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib Mesylate
Description: Given PO
Study NCT02812693 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02812693 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT04712695 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Based Interventions
Description: Proprioception Training Interventions
Study NCT04712695 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Exercise Based Interventions
Description: Proprioception Training Interventions
Study NCT04850872 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PLAYwithHEART Programme for adolescent athletes
Description: PLAYwithHEART programme for adolescent athletes is an intervention programme based on Mindfulness, Acceptance, and Compassion for adolescent athletes
Study NCT04389151 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Toripalimab
Description: Toripalimab union CAPEOX scheme： Toripalimab 240mg, ivgtt, Q3w Oxaliplatin 130mg/m2,ivgtt, Q3w capecitabine 1000mg/m2, p.o Q3w
Study NCT01014208 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OFATUMUMAB + DHAP
Description: 3 cycles of treatment will be administered. Each cycle will last 21 days. ofatumumab dose: cycle 1, day 1 - 1000 mg; cycle 1, day 8 - 1000 mg; cycle 2, day 1 and cycle 3, day 1 - 1000 mg. DHAP regimen: dexamethasone - 40 mg on days 1, 2, 3, and 4 of dosing cycle; cisplatin - 100 mg/m2/24hrs continuous on day 1 of dosing cycle; cytarabine - 2g/m2 q12 hrs (2 doses) on day 2 of dosing cycle.
Study NCT01014208 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RITUXIMAB + DHAP
Description: 3 cycles of treatment will be administered. Each cycle will last 21 days. rituximab dose: cycle 1, day 1 - 375 mg/m2; cycle 1, day 8 - 375 mg/m2; cycle 2, day 1 and cycle 3, day 1 - 375 mg/m2. DHAP regimen: dexamethasone - 40 mg on days 1, 2, 3, and 4 of dosing cycle; cisplatin - 100 mg/m2/24hrs continuous on day 1 of dosing cycle; cytarabine - 2g/m2 q12 hrs (2 doses) on day 2 of dosing cycle.
Study NCT04019990 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: The effect of throwers ten exercise programme on wheelchair basketball and ambulant basketball players
Description: Throwers Ten exercise programme is a programme designed to improve the power, strength and endurance of large muscle groups required for the throwing activity. It consists of exercises involving the movement of upper limb joints in full range of joint motion or at specified specific angles, with the help of a resistance band and weights specific to individual athletes. In the literature, no study has demonstrated the effectiveness of Throwers Ten exercise programme in wheelchair basketball and ambulant basketball players.
Study NCT01994837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-199
Description: Tablet
Study NCT01169740 — intervention group
Intervention type: PROCEDURE
Intervention: Measurement of bilirubin in blood and skin color
Description: Blood sampling and analysis, measurement of skin color by transcutaneous bilirubinometry
Study NCT01165853 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Glucose
Description: 25% dose at 8-week intervention assigned to subjects.
Study NCT01165853 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Fructose
Description: 25% dose at 8-week intervention assigned to subjects.
Study NCT01290289 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Epidura, CSE & IV
Description: Gp 1: received CSE analgesia: 25µg of fentanyl \& a bolus dose of 10 ml of 0.5% lidocaine was injected epidurally. E top-ups of 5-10 ml of 0.5-0.8% lidocaine were then injected.~Gp 2: received CSE analgesia: 25µg of fentanyl \& a bolus dose of 10 ml of 0.0625% bupivacaine was injected epidurally. E top-ups of 5-10 ml of 0.0625-0.25% bupivacaine were then injected.~Gp 3: received 50µg of E fentanyl analgesia \& a bolus of 10 ml of 0.5% lidocaine was administered, followed by lidocaine E top-ups of 5-10 ml of 0.5-0.8%.~Gp 4: received analgesia: 50µg of E fentanyl \& a bolus dose of 10 ml of 0.125% bupivacaine was administered, followed by E bupivacaine top-ups of 5-10 ml of 0.125-0.25%.~Gp 5: 50mg of IV pethidine was administered as loading dose, followed by 0.5 mg/kg.
Study NCT01985451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexe
Description: Patients with relapsed PCNSL patients were treated with high-dose pemetrexed (900mg/m²).
Study NCT03265795 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Poly Ether Ether Ketone PSI (patient specific implant).
Description: reconstruction of the bone and the original volume of maxillary sinus accurately (in terms of clinical and radiographic parameters).
Study NCT03133013 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: SLEEPSCOPE
Description: Brainwave measurement device which is connected to the participant by an electrode attached to the forehead and another electrode behind one ear
Study NCT01985451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Patients with relapsed PCNSL patients were treated with temozolomide (200mg/m² day 1-5,28).
Study NCT03114839 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus casei strain Shirota (LcS)
Description: A fermented milk containing LcS, 65 ml for oral administration, 1 bottle per day for 7 days. One bottle of the drink contains: 42.9 kcal/182 kJ; less than 0.1 g of fat; 9.6 g of carbohydrate; 0.01 g of sodium; 0.9 g of protein; and at least 6.5 x 10\^9 colony-forming units of LcS.
Study NCT03780218 — intervention group
Intervention type: OTHER
Intervention: Respiratory function
Description: Respiratory function test evaluates the participants' pulmonary function and respiratory muscle strength
Study NCT03695939 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: realSKIN (skin xenotransplant)
Description: 3+3 Dose-escalation Study Design; 2 dosage strengths will be utilized during this Phase 1/2 Trial; an expansion cohort (9 patients) receive the highest dose.
Study NCT03695939 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Human Cadaver Allograft
Description: HCA is used as a temporary wound dressing between debridement and definitive closure in many well-resourced contexts.
Study NCT03601377 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training away from threat
Description: Dot-probe task: Pairs of stimuli, angry - neutral face or neutral - neutral faces of the same actor (20 different individuals;10 male, 10 female) are presented horizontally in the centre of the screen (160 trials; 120 angry-neutral and 40 neutral-neutral). Each trial begins with a fixation cross (500 ms), on which the participants are instructed to focus their gaze. After that a pair of faces follows which is presented on the screen for 500ms. After the faces presentation a small visual probe (\< or >) appears at the same place of one of the two faces. Participants have to determine which symbol appeared by clicking right or left on the mouse as quickly as possible. The target probe remains on the screen until there is a response, which starts a new trial.
Study NCT03601377 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training towards threat
Description: Dot-probe task: Pairs of stimuli, angry - neutral face or neutral - neutral faces of the same actor (20 different individuals;10 male, 10 female) are presented horizontally in the centre of the screen (160 trials; 120 angry-neutral and 40 neutral-neutral). Each trial begins with a fixation cross (500 ms), on which the participants are instructed to focus their gaze. After that a pair of faces follows which is presented on the screen for 500ms. After the faces presentation a small visual probe (\< or >) appears at the same place of one of the two faces. Participants have to determine which symbol appeared by clicking right or left on the mouse as quickly as possible. The target probe remains on the screen until there is a response, which starts a new trial.
Study NCT03601377 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dot-probe task: Pairs of stimuli, angry - neutral face or neutral - neutral faces of the same actor (20 different individuals;10 male, 10 female) are presented horizontally in the centre of the screen (160 trials; 120 angry-neutral and 40 neutral-neutral). Each trial begins with a fixation cross (500 ms), on which the participants are instructed to focus their gaze. After that a pair of faces follows which is presented on the screen for 500ms. After the faces presentation a small visual probe (\< or >) appears at the same place of one of the two faces. Participants have to determine which symbol appeared by clicking right or left on the mouse as quickly as possible. The target probe remains on the screen until there is a response, which starts a new trial.
Study NCT04723914 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: dual target CAR-T cell therapy
Description: CD19/CD20 dual target CAR-T cell therapy
Study NCT03237572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab (200 mg)
Study NCT03237572 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-intensity focused ultrasound (HIFU)
Description: Ablation will target 50% of the tumor, up to 3 cubic centimeters
Study NCT02754349 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SphygmoCor version 7, AtCor Medical, Sydney, Australia
Description: Pulse wave velocity, augmentation index and central blood pressure measurement with applanation tonometry before and after electrical cardioversion
Study NCT00480402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 200 mg of Progesterone
Description: Administration of 200 mg of Progesterone
Study NCT00480402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 400 mg Progesterone
Description: Administration of 400 mg Progesterone
Study NCT00480402 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Administration of a Placebo
Study NCT03133013 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SLEEPSCOPE
Description: Brainwave measurement device which is connected to the participant by an electrode attached to the forehead and another electrode behind one ear
Study NCT01294813 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical Impedance Tomography (EIT)
Description: EIT measurements of 1-2 minutes are performed in patients who routinely undergo bronchoscopy (during 1.5 hours) before, directly after and 10, 30, 60 minutes after bronchoscopy. Therefore the rubber belt including 16 integrated electrographic electrodes is placed around the patient´s chest and connected with an EIT device. EIT data are generated by application of a small alternating current of 5mA and 50kHz and are stored and analyzed offline on a personal computer. Pseudonomyzed EIT data are evaluated descriptively.
Study NCT01885065 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gel-based artificial saliva
Description: Gel-based artificial saliva is an edible non-nutritious gel intended to relieve dry mouth.~Taking orally 1-2 teaspoon each time, 5 times / day (30-50 ml/ day) for four weeks.
Study NCT04425317 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Blood sample
Description: Blood sample and endometrial biopsy on the moment of oocyte retrieval
Study NCT03415178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alirocumab SAR236553
Description: Pharmaceutical form: Solution for injection Route of administration: Subcutaneous
Study NCT03415178 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Current auto-injector device (AI)
Description: Pharmaceutical form:~Route of administration: Subcutaneous self-administration of alirocumab
Study NCT03415178 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: New auto-injector device (SYDNEY)
Description: Pharmaceutical form:~Route of administration: Subcutaneous self-administration of alirocumab
Study NCT03415178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Pharmaceutical form:tablet Route of administration: oral
Study NCT03415178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Pharmaceutical form:tablet Route of administration: oral
Study NCT01978756 — intervention group
Intervention type: OTHER
Intervention: Outpatient clinic
Description: The participants are seen at the outpatient clinic by a physician or a physician assistant. To analyse fibrosis clinical examination of the breast will be performed. To analyse shoulder function anteversion / retroversion, abduction / adduction and internal / external rotation will be measured. To analyse edema the arm circumference will be measured 15 cm above and below the medial epicondyle (both sides). Also, a photograph of the breast will be made for cosmetic analysis using standardized procedures. Finally a blood sample or saliva will be obtained, if the patient has given written informed consent to participate in the Biobank.
Study NCT02587936 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Collaborative Model of Primary care and Subspecialty care
Description: Pieces will access Electronic Health Record for all patients receiving care at the participating sites to detect patients with a triad of chronic kidney disease, diabetes and hypertension, facilitate management and monitor outcomes. To maximize successful implementation of care, a Practice Facilitator will be at each site with standardized role training using a curriculum based on the Agency for Healthcare Research and Quality (AHRQ) Practice Facilitation Handbook. Specific interventions are maintaining BP less than 140/90 mmHg, use of angiotensin-converting-enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB), treatment with statins, aiming for glycosylated Hemoglobin (HgA1C) at the recommended target, and avoiding nephrotoxic medications. Additional interventions include chronic kidney disease education for Primary Care Providers (PCP) and patients using National Kidney Disease Education Program (NKDEP) materials.
Study NCT02577029 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARC-520
Description: ARC-520 will be administered intravenously concomitantly with 0.9% normal saline using an infusion rate of 0.4 mL/min (24 mL/hour) for study treatment and 200 mL/hr for saline.
Study NCT02577029 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: entecavir
Description: 0.5 mg once daily; oral
Study NCT02577029 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pegylated interferon alpha 2a
Description: 180 mcg; subcutaneous injection once weekly
Study NCT02577029 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tenofovir disoproxil
Description: 300 mg once daily; oral
Study NCT02577029 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: antihistamine
Description: All participants will be pre-treated with an oral antihistamine selected by the investigator from the list of approved antihistamines that is available in that country. Acceptable antihistamines are: diphenhydramine 50 mg p.o., chlorpheniramine 8 mg p.o., hydroxyzine 50 mg p.o., or cetirizine 10 mg p.o.
Study NCT03573297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cariprazine
Description: Cariprazine capsules, oral administration, once daily
Study NCT03573297 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo capsules, oral administration, once daily
Study NCT02078817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: IV infusions of 0.5mg/kg of Ketamine hydrochloride over a 40-minute infusion period. Participants will receive a total of 6 doses over a 2-week period.
Study NCT02943213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorpromazine Hydrochloride
Description: Chlorpromazine Hydrochloride (25 mg Tablet) - Generic US Applicant holder is USL Pharma Inc.
Study NCT00700635 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Menactra®: Meningococcal Polysaccharide Diphtheria Conjugate
Description: 0.5 mL, 2 doses Intramuscular
Study NCT00700635 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Menactra®: Meningococcal Polysaccharide Diphtheria Conjugate
Description: 0.5 mL, 1 dose Intramuscular
Study NCT02552940 — intervention group
Intervention type: DRUG
Intervention: Tocilizumab
Description: Participants with RA receive TCZ SC, as per routine clinical practice and are followed for approximately 6 months.
Study NCT02366416 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: Physical activity
Study NCT00193908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cavilon (TM) Durable Barrier Cream
Description: Cavilon (TM) Durable Barrier Cream will be applied to either the medial or the lateral side of the treated breast. Side will depend on randomisation.
Study NCT00193908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorbolene
Description: Sorbolene will be applied to either the medial or the lateral side of the treated breast. Side will be determined by randomisation
Study NCT00193908 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Minimum prescribed dose to the chest wall is 45Gy in 25 fractions. Planning and Treatment is per the study protocol
Study NCT02676804 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-intensity, aerobic exercise.
Description: Aerobic exercise will blend unsupervised moderate and supervised high intensity exercise. It will consist of walking/jogging modalities, dependent on the subject's level of bradykinesia, paced by the subject's level of perceived exertion. The exercise protocol will be designed to target an total of at least 150 minutes of cardio exercise per week.~Exercise training will be performed 5 times per week for 6 weeks, consisting of 3 supervised high intensity sessions and 2 at home moderate intensity sessions. High intensity sessions will be performed on a treadmill at an intensity rating of \~ 15 and 17 on a rating of perceived exertion (RPE) scale of 6 to 20. The moderate intensity exercise will target an RPE of \~10 - 12 and participants will be asked to complete this on their own.
Study NCT00988780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: maraviroc
Description: Maraviroc 600mg po BID every day from the entry visit until week 48 or until IRIS event or unacceptable toxicity develops.~Efavirenz 600 mg qd every day from the entry visit until week 48 or until IRIS event or unacceptable toxicity develops.~Tenofovir/Emtricitabine 300/200 mg qd from the entry visit until week 48 or until IRIS event or unacceptable toxicity develops.
Study NCT00988780 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets po BID every day from the entry visit until week 48 or until IRIS event or unacceptable toxicity develops.~Efavirenz 600 mg qd every day from the entry visit until week 48 or until IRIS event or unacceptable toxicity develops.~Tenofovir/Emtricitabine 300/200 mg qd from the entry visit until week 48 or until IRIS event or unacceptable toxicity develops.
Study NCT04480528 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood Flow Restriction Training (BFRT)
Description: A pressurized cuff is applied to the proximal thigh in order to partially occlude blood flow as the patient exercises.
Study NCT04480528 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Blood Flow Restriction Training (Sham BFRT)
Description: A minimally pressurized cuff is applied to the proximal thigh in order to mimic the active blood flow restriction unit as the patient exercises.
Study NCT01831843 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Group C
Description: non-heated, non-humidified conventional breathing circuit was used in group C patient
Study NCT01831843 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Group E
Description: breathing tube which apply humidity and heat (Evaqua™ Breathing Circuits manufactured by Fischer \& Paykel)was used in group E patient
Study NCT01831843 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Group M
Description: Heated humid tube with a warming device (Mega Acer kit manufactured by Acemedical,Seoul Korea)was used in group M patient
Study NCT04005768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine Sulphate
Description: After a stabilization period of 20 min and 10 min after the first blood collection, Plaquenil (Hydroxychloroquine sulfate) will be administered per os (total dose of 400 mg) in a randomized, double-blinded fashion.
Study NCT04005768 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: After a stabilization period of 20 min and 10 min after the first blood collection, Placebo will be administered per os (2 tablets) in a randomized, double-blinded fashion.
Study NCT04291040 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Decision Aid
Description: Following randomization, participants will independently view the multimedia based decision aid on a provided tablet. They will also receive provider counseling. For the remainder of the pregnancy, they will receive a text message with a link to the multimedia based presentation. This will occur every 4 weeks until 12 weeks postpartum.
Study NCT04291040 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Routine Care
Description: The control arm will receive routine prenatal care including provider counselling on postpartum contraceptive options.
Study NCT01173172 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Boron Neutron Capture Therapy
Description: Boronophenylalanine (BPA) 500 mg/kg on D1 and D30 followed by BNCT for 2 fractions (D1 and D30)
Study NCT01953991 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dentures
Description: Removable prosthesis to replace missing teeth